Processa Pharmaceuticals Inc
processapharmaceuticals.comWhat Do They Do?
Develops small-molecule cancer drug candidates for patients, designed to alter how existing cancer drugs are processed or distributed, plus candidates for gastroparesis and kidney disease.
10-K for FY2025, filed Mar 18, 2026We are a publicly listed clinical-stage biopharmaceutical company. We are developing a pipeline of Next Generation Cancer therapy (“NGC”)…View ↗
Our risk-mitigated strategy is to identify existing effective cancer therapies where the active cancer-killing ingredients are well…View ↗
PCS12852 is a highly specific and potent 5HT4 agonist that is Phase 2B ready as a meaningful treatment for gastroparesis patients.…View ↗
PCS499 is a drug that can be used to treat unmet medical need conditions caused by multiple pathophysiological changes. We are presently…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.3MView ↗
- ▼ −17% (Loss)
- vs −$3.9M in Q2 FY2025
-
Jul 29, 2026
Acquired Vidya Therapeutics and added its VT-7208 drug candidate
The acquisition adds a BTK inhibitor program for immune-mediated diseases; a concurrent private placement was expected to raise approximately $200 million.
Sources
8-K, filed Jul 29, 2026
VERO BEACH, FL, JULY 29, 2026 – Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya…View ↗
Loading...
